Application 761123

Type
BLA
Sponsor
ASTRAZENECA AB

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761123Saphneloanifrolumab-fnia351(a)Rx2026-07-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001SAPHNELOANIFROLUMAB-FNIAINJECTABLE;INJECTION300MG/2ML(150MG/ML)NoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
SAPHNELOANIFROLUMAB-FNIAAstraZeneca Pharmaceuticals LPd6203302-2128-41a7-b0b4-0e6c0704d4dc2026-04-24Warnings, Adverse reactionsExact identifier
application number: BLA761123
ndc (product): 0310-3040

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 4 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent
0310-3040SAPHNELOAnifrolumabAstraZeneca Pharmaceuticals LPBLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
79353SUPPL 2024-08-09
79339SUPPL 2024-08-08
76728SUPPL 2023-12-05
76722SUPPL 2023-12-04
68390ORIG2021-08-17
68261ORIG2021-08-02
68232ORIG2021-08-02